miRagen Therapeutics In Strategic, Funding Deal With Servier

Boulder-based miRagen Therapeutics said this week that it has inked a strategic deal with French pharmaceutical company Servier. According to the companies, they have extended a research collaboration on discovering, developing, and commercializing drugs targeting microRNAs for cardiovascular disease. Financial details of the deal were not announced, however, miRagen reported a $7M fundraising in an SEC filing this week. The two said the deal will extend its collaboration to October of 2016. miRagen is led by William S. Marshall. The company is backed by Amgen Ventures, Atlas Venture, Boulder Ventures, Broadview Ventures, Remeditex Ventures, and The Perierls Foundation.